(NASDAQ: SGMT) Sagimet Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Sagimet Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast SGMT's revenue for 2027 to be $124,274,032, with the lowest SGMT revenue forecast at $124,274,032, and the highest SGMT revenue forecast at $124,274,032. On average, 3 Wall Street analysts forecast SGMT's revenue for 2028 to be $2,440,503,737, with the lowest SGMT revenue forecast at $1,573,386,510, and the highest SGMT revenue forecast at $2,989,015,830.
In 2029, SGMT is forecast to generate $6,348,149,346 in revenue, with the lowest revenue forecast at $3,781,021,317 and the highest revenue forecast at $11,078,418,215.